Vicore Appoints Leading Respiratory Medicine Developer Dr. Bertil Lindmark MD, PhD, as Chief Medical Officer

Vicore continues to strengthen its leadership in idiopathic pulmonary fibrosis (IPF) drug development by appointing Dr. Lindmark as its new Chief Medical Officer
Lindmark brings deep expertise in late-stage clinical development for respiratory diseases, having developed Symbicort and several other global respiratory brands
Appointment reflects Vicore’s advancement to late-stage development in IPF, following the interim phase 2a AIR data read-out showing potential for improving lung function

Locations